.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB03_AgalsidaseAlfa.AgalsidaseAlfa .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB03_AgalsidaseAlfa.AgalsidaseAlfa| name: | AgalsidaseAlfa | |
| ATC code: | A16AB03 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 0.2 | mg |
| volume of distribution: | 3.6 | L |
| clearance: | 2.1 | L/h |
| other parameters in model implementation | ||
Agalsidase alfa is a recombinant human alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a rare X-linked lysosomal storage disorder characterized by deficient activity of the alpha-galactosidase A enzyme. It helps to reduce the accumulation of globotriaosylceramide (GL-3) in various tissues. Agalsidase alfa is approved and in current clinical use for long-term enzyme replacement therapy in patients with Fabry disease.
Pharmacokinetic parameters reported in adult patients with Fabry disease after intravenous infusion of agalsidase alfa 0.2 mg/kg. Parameters from population pharmacokinetics and noncompartmental analyses.